In 2036, Investors Will Regret Not Loading Up on This Multibagger in the Making

Regeneron's shares are positioned to rise, thanks to the performance of its pipeline. Its top-selling drug, Dupixent, has already been approved for nine indications.

The Motley Fool • Mar 12, 2026

Regeneron Pharmaceuticals, Inc. (REGN) Presents at Leerink Global Healthcare Conference 2026 Transcript

Regeneron Pharmaceuticals, Inc. (REGN) Presents at Leerink Global Healthcare Conference 2026 Transcript

Seeking Alpha • Mar 11, 2026

Regeneron: Fairly Valued Now After A Stellar Upswing

Regeneron Pharmaceuticals, Inc. is rated a long-term Buy, but I expect near-term sideways trading due to limited new catalysts. Declining Eylea/Eylea HD revenues are largely offset by strong Dupixent growth, with Dupixent likely to exceed 50% of total revenue by 2027. Libtayo and pipeline assets show promise, but meaningful revenue impact is expected only after 2026; diversification into new areas brings both opportunity and capital allocation risk.

Seeking Alpha • Mar 11, 2026

Regeneron Pharmaceuticals, Inc. (REGN) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Regeneron Pharmaceuticals, Inc. (REGN) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Seeking Alpha • Mar 10, 2026

Regeneron Science Talent Search 2026 Recognizes America's Top Young Scientists, Awarding More Than $1.8 Million to High School Seniors for Innovative Research in Computational Mathematics, Neural Science, and Blood Cancer Treatment

Regeneron and Society for Science announced that Connor Hill, 17, of State College, PA, won the top $250,000 award in the Regeneron Science Talent Search

GlobeNewsWire • Mar 11, 2026

2 Underrated Weight Loss Stocks to Buy Now

Regeneron has a pair of weight-loss candidates close to entering late-stage studies. Roche's recent mid-stage readout positions it as a strong contender in the weight loss market.

The Motley Fool • Mar 8, 2026

2 Biotech Giants to Buy in 2026

These companies will offer you the fantastic combination of growth and safety. They're both trading at reasonable prices right now.

The Motley Fool • Mar 5, 2026

Regeneron Pharmaceuticals, Inc. (REGN) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Regeneron Pharmaceuticals, Inc. (REGN) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Seeking Alpha • Mar 4, 2026

REGN & SNY's Dupixent Gets CHMP Nod for Pediatric Use in Urticaria

Regeneron and Sanofi win CHMP backing to expand Dupixent use to young CSU patients, with EU and U.S. decisions poised to unlock a new growth avenue.

Zacks Investment Research • Mar 2, 2026

10 Best CEFs This Month: Average Yield Of 9.7% (February 2026)

The article presents a rigorously screened list of 10 top closed-end funds, or CEFs, for income investors, offering an average 9.7% yield and -10% NAV discount. Selections emphasize sector diversification, long-term outperformance, sustainable distributions, and attractive valuations, with a focus on both equity and credit-oriented CEFs. CEFs are generally characterized by higher volatility and deeper drawdowns than the broader market. For these reasons, they are not suited for everyone.

Seeking Alpha • Feb 28, 2026